» Articles » PMID: 21603631

Purification and Characterization of Enterovirus 71 Viral Particles Produced from Vero Cells Grown in a Serum-free Microcarrier Bioreactor System

Overview
Journal PLoS One
Date 2011 May 24
PMID 21603631
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Enterovirus 71 (EV71) infections manifest most commonly as a childhood exanthema known as hand-foot-and-mouth disease (HFMD) and can cause neurological disease during acute infection.

Principal Finding: In this study, we describe the production, purification and characterization of EV71 virus produced from Vero cells grown in a five-liter serum-free bioreactor system containing 5 g/L Cytodex 1 microcarrier. The viral titer was >10(6) TCID(50)/mL by 6 days post infection when a MOI of 10(-5) was used at the initial infection. Two EV71 virus fractions were separated and detected when the harvested EV71 virus concentrate was purified by sucrose gradient zonal ultracentrifugation. The EV71 viral particles detected in the 24-28% sucrose fractions had an icosahedral structure 30-31 nm in diameter and had low viral infectivity and RNA content. Three major viral proteins (VP0, VP1 and VP3) were observed by SDS-PAGE. The EV71 viral particles detected in the fractions containing 35-38% sucrose were 33-35 nm in size, had high viral infectivity and RNA content, and were composed of four viral proteins (VP1, VP2, VP3 and VP4), as shown by SDS-PAGE analyses. The two virus fractions were formalin-inactivated and induced high virus neutralizing antibody responses in mouse immunogenicity studies. Both mouse antisera recognized the immunodominant linear neutralization epitope of VP1 (residues 211-225).

Conclusion: These results provide important information for cell-based EV71 vaccine development, particularly for the preparation of working standards for viral antigen quantification.

Citing Articles

Preparation and immunoprotective effects of a virus-like particle candidate vaccine of the dominant epidemic D3 genotype coxsackievirus A6 in China.

Li X, Xu X, Li J, Lu H, Wang C, Wang R Biosaf Health. 2025; 6(1):28-34.

PMID: 40078305 PMC: 11894959. DOI: 10.1016/j.bsheal.2023.11.001.


Substitution of Coxsackievirus A16 VP1 BC and EF Loop Altered the Protective Immune Responses in Chimera Enterovirus A71.

Tan X, Chong W, Lee V, Abdullah S, Jasni K, Suarni S Vaccines (Basel). 2023; 11(8).

PMID: 37631931 PMC: 10458053. DOI: 10.3390/vaccines11081363.


Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system.

Lien S, Shen Y, Lin H, Wu S, Fang C, Chen C Virus Res. 2023; 329:199101.

PMID: 36958398 PMC: 10194310. DOI: 10.1016/j.virusres.2023.199101.


The Bottlenecks of Preparing Virus Particles by Size Exclusion for Antibody Generation.

Lee C, Huang P, Mwale P, Wang W, Leu S, Tseng S Int J Mol Sci. 2022; 23(21).

PMID: 36361757 PMC: 9653933. DOI: 10.3390/ijms232112967.


Development of a rapid neutralization testing system for Rhinovirus C15 based on the enzyme-linked immunospot assay.

Zhou Z, Zhu R, Yang H, Xu L, Chen H, Wu Y Front Microbiol. 2022; 13:983656.

PMID: 36212859 PMC: 9539532. DOI: 10.3389/fmicb.2022.983656.


References
1.
Liu C, Lian W, Butler M, Wu S . High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2006; 25(1):19-24. DOI: 10.1016/j.vaccine.2006.06.083. View

2.
SCHMIDT N, LENNETTE E, Ho H . An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974; 129(3):304-9. DOI: 10.1093/infdis/129.3.304. View

3.
Qiu J . Enterovirus 71 infection: a new threat to global public health?. Lancet Neurol. 2008; 7(10):868-9. PMC: 7128195. DOI: 10.1016/S1474-4422(08)70207-2. View

4.
Wu S, Liu C, Lian W . Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine. 2004; 22(29-30):3858-64. DOI: 10.1016/j.vaccine.2004.05.037. View

5.
Von Seefried A, Chun J, Grant J, Letvenuk L, Pearson E . Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. Rev Infect Dis. 1984; 6 Suppl 2:S345-9. PMC: 7792939. DOI: 10.1093/clinids/6.supplement_2.s345. View